Skip Navigation



NDT Plus Advance Access published online on November 12, 2008
NDT Plus, doi:10.1093/ndtplus/sfn169
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
2/1/49    most recent
sfn169v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Lehmann, G.
Right arrow Articles by Wolf, G.
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2008]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Bone histomorphometry after treatment with teriparatide (PTH 1-34) in a patient with adynamic bone disease subsequent to parathyroidectomy

Gabriele Lehmann1, Undine Ott1, Jörg Maiwald2 and Gunter Wolf1

1 Department of Internal Medicine III, Friedrich Schiller University of Jena
2 Dialysis Center and Nephrological Surgery, Gera, Germany

Correspondence: Correspondence and offprint requests to: Gabriele Lehmann, Department of Internal Medicine III, Friedrich Schiller University of Jena, Erlanger Allee 101, 07747 Jena, Germany. Tel: +49-3641-9324327; Fax: +49-3641-9324362; E-mail: gabriele.lehmann{at}med.uni-jena.de


  Abstract

A 33-year-old male patient suffered from adynamic bone disease because of parathyroidectomy due to tertiary hyperparathyroidism. Histomorphometric analysis of bone biopsies taken before and 8 months after treatment with teriparatide (human parathyroid hormone 1-34 of recombinant DNA origin) for 18 months is demonstrated. A considerable increase in mineralized bone volume and also stimulated bone remodelling were detected after treatment with teriparatide. Although teriparatide is currently only licenced for treatment of severe osteoporosis, this case shows the potential therapeutic effect of this new drug to improve bone structure in a patient with adynamic bone disease.

Key Words: adynamic bone disease • end-stage renal disease • histomorphometry • teriparatide therapy

Received for publication September 21, 2008. Accepted for publication October 15, 2008.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.